» Articles » PMID: 35934727

Drug Repurposing: Re-inventing Therapies for Cancer Without Re-entering the Development Pipeline-a Review

Overview
Specialty Oncology
Date 2022 Aug 7
PMID 35934727
Authors
Affiliations
Soon will be listed here.
Abstract

While majority of the current treatment approaches for cancer remain expensive and are associated with several side effects, development of new treatment modalities takes a significant period of research, time, and expenditure. An alternative novel approach is drug repurposing that focuses on finding new applications for the previously clinically approved drugs. The process of drug repurposing has also been facilitated by current advances in the field of proteomics, genomics, and information computational biology. This approach not only provides cheaper, effective, and potentially safer drugs with less side effects but also increases the processing pace of drug development. In this review, we wish to highlight some recent developments in the area of drug repurposing in cancer with a specific focus on the repurposing potential of anti-psychotic, anti-inflammatory and anti-viral drugs, anti-diabetic, antibacterial, and anti-fungal drugs.

Citing Articles

Exploiting the Achilles' heel of cancer through a structure-based drug-repurposing approach and experimental validation of top drugs using the TRAP assay.

Kaur D, Chopra M, Saluja D Mol Divers. 2025; .

PMID: 40087255 DOI: 10.1007/s11030-025-11162-1.


Navigating Metabolic Challenges in Ovarian Cancer: Insights and Innovations in Drug Repurposing.

Mikhael S, Daoud G Cancer Med. 2025; 14(4):e70681.

PMID: 39969135 PMC: 11837049. DOI: 10.1002/cam4.70681.


Repurposing fluvoxamine as an inhibitor for NUDT5 in breast cancer cell: an in silico and in vitro study.

Ramasamy S, Jeyaram K, Narayanan A, Arunachalam S, Ethiraj S, Sankar M In Silico Pharmacol. 2024; 13(1):5.

PMID: 39726906 PMC: 11668718. DOI: 10.1007/s40203-024-00293-2.


Drug Repurposing for Cancer Treatment: A Comprehensive Review.

Al Khzem A, Gomaa M, Alturki M, Tawfeeq N, Sarafroz M, Alonaizi S Int J Mol Sci. 2024; 25(22).

PMID: 39596504 PMC: 11595001. DOI: 10.3390/ijms252212441.


Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.

Dhas Y, Biswas N, M R D, Jones L, Ashili S Mol Biomed. 2024; 5(1):40.

PMID: 39333445 PMC: 11436690. DOI: 10.1186/s43556-024-00204-z.


References
1.
Chaudhury A, Duvoor C, Dendi V, Kraleti S, Chada A, Ravilla R . Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front Endocrinol (Lausanne). 2017; 8:6. PMC: 5256065. DOI: 10.3389/fendo.2017.00006. View

2.
Jourdan J, Bureau R, Rochais C, Dallemagne P . Drug repositioning: a brief overview. J Pharm Pharmacol. 2020; 72(9):1145-1151. PMC: 7262062. DOI: 10.1111/jphp.13273. View

3.
Zhang Q, Liu F, Zeng M, Mao Y, Song Z . Drug repurposing strategies in the development of potential antifungal agents. Appl Microbiol Biotechnol. 2021; 105(13):5259-5279. PMC: 8214983. DOI: 10.1007/s00253-021-11407-7. View

4.
Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T . Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep. 2018; 8(1):15753. PMC: 6202417. DOI: 10.1038/s41598-018-33740-0. View

5.
Sokolova O, Naumann M . NF-κB Signaling in Gastric Cancer. Toxins (Basel). 2017; 9(4). PMC: 5408193. DOI: 10.3390/toxins9040119. View